8-K filing — Co-Diagnostics, Inc. (CODX)
Filed: 2026-11-10 AccNo: 0001493152-26-050868 Size: 311 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Co-Diagnostics Q3 EPS $(1.01) Beats $(1.25) Estimate, Sales $282.881K Beat $169.000K Estimate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast
Co-Diagnostics, Inc. has rescheduled its third quarter 2026 financial results release and conference call to November 10, 2026.
Co-Diagnostics Expands South Asian Market Presence via CoSara
Co-Diagnostics, Inc. is expanding its reach in India and South Asia through its joint venture, CoSara Diagnostics, with plans for a direct sales team and upcoming regulatory milestones.
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date
Co-Diagnostics, Inc. will release its third quarter 2026 financial results on November 12, 2026.
Co-Diagnostics Announces Publication Of Peer-Reviewed Study Using SARAGENE Human Papillomavirus High Risk Test Manufactured By CoSara Diagnostics